CytomX Therapeutics, Inc. (NASDAQ: CTMX) is a Healthcare company (Biotechnology) with a market capitalization of $423M. The Maz Rating grades it against the other companies in its sector.
CytomX Therapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $1.94, CytomX Therapeutics, Inc. trades at 30.0x sales and 1.5x book value. Over the last twelve months it generated about $14M of revenue and a net loss of $99M. It runs a gross margin of 98.2%, an operating margin of -676.5% and a net margin of -609.0%. It shows return on equity of -34.0%, return on invested capital of -29.7% and a free cash flow yield of -12.1%. On the balance sheet: a debt-to-equity ratio of 0.02 and a current ratio of 7.82. Over the past 52 weeks the share price ranged from $1.90 to $8.21, with a beta of 2.24.
CytomX Therapeutics, Inc. does not currently pay a dividend.
21 Wall Street analyst ratings cover the stock: 17 Buy and 4 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.